Olivares-Hernandez, AlejandroDel-Barco-Morillo, EdelMiramontes-Gonzalez, Jose PabloFiguero-Perez, LuisPerez-Belmonte, LuisMartin-Vallejo, JavierMartin-Gomez, TeresaEscala-Cornejo, RobertoVidal-Tocino, RosarioBellido-Hernandez, LorenaGonzalez-Sarmiento, RogelioLudeña-de-la-Cruz, Maria DoloresCruz-Hernandez, Juan JesusParra-Perez, Carmen2023-05-032023-05-032022-03-08Olivares-Hernández A, Del Barco Morillo E, Miramontes-González JP, Figuero-Pérez L, Pérez-Belmonte L, Martín-Vallejo J, et al. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy. Front Biosci (Landmark Ed). 2022 Mar 8;27(3):88http://hdl.handle.net/10668/21810Determining predictive biomarkers for immune checkpoint inhibitors (ICIs) is a current challenge in oncology. Previous studies on non-small cell lung cancer (NSCLC) have shown how TP53 gene mutations are correlated with different responses to ICIs. Strong and diffuse immuno-expression of p53 by immunohistochemistry (IHC) is interpreted as a likely indicator of a TP53 gene mutation. We aimed to assess the p53 protein expression via IHC in NSCLC as a predictive biomarker of the response to ICIs. This was a retrospective hospital-based study of patients with NSCLC treated with Nivolumab in the University Hospital of Salamanca. All diagnostic biopsies were studied via IHC (measuring p53 protein expression, peroxidase anti-peroxidase immunohistochemistry technique using Leica BOND Polymer development kits). Survival analysis was performed by subgroups of expression of p53 and other factors using the Kaplan-Meier estimator and Cox proportional-hazards model. Seventy-three patients were included (59 men and 14 women). The median age was 68 (44-84) years. Thirty-six biopsies were adenocarcinoma, 34 were squamous, and three were undifferentiated. In 41 biopsies (56.2%), the cellular expression of p53 was A trend toward a greater response to ICIs was observed in the PFS and OS of patients with high expression of p53 by IHC (TP53 mutation), especially in the PD-L1 negative adenocarcinoma subgroup. These results will make it possible to make future modifications to the clinical guidelines of NSCLC according to the expression of p53.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/BiomarkersImmune checkpoint inhibitorsImmunotherapyNon-small cell lung cancerp53 proteinAdenocarcinomaAdultAgedAged, 80 and overB7-H1 AntigenCarcinoma, Non-Small-Cell LungFemaleHumansImmunotherapyLung NeoplasmsMaleMiddle AgedRetrospective StudiesTumor Suppressor Protein p53research article35345320open accessBiopsiaMutaciónInmunohistoquímicaAdenocarcinomaCarcinoma de Pulmón de Células no PequeñasInhibidores de Puntos de Control Inmunológico10.31083/j.fbl27030882768-6698https://www.imrpress.com/journal/FBL/27/3/10.31083/j.fbl2703088/pdf